The Canadian Agency for Drugs and Technologies in Health (CADTH) Scientific Advice program is a voluntary, fee-for-service consultation offered to pharmaceutical companies to provide advice on early drug development plans from a health technology assessment (HTA) perspective. CADTH Scientific Advice is provided at the request of the applicant. The application for CADTH Scientific Advice constitutes the applicant’s agreement with the program policies, guidelines, and processes, including this disclaimer, as specified on the website. CADTH Scientific Advice is provided in response to specific questions and issues raised by the applicant. CADTH Scientific Advice is based on information submitted by the applicant, as well as on other material publicly available at the time that Scientific Advice is provided.

While CADTH has taken care to ensure that the Scientific Advice provided is accurate, complete, and up-to-date at the time it is provided, CADTH does not make any guarantee to that effect. CADTH Scientific Advice cannot account for future changes in scientific knowledge, clinical standards of practice, regulatory requirements, and HTA methodology. CADTH Scientific Advice is intended for use in the context of the Canadian health care system. CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the Scientific Advice or any of the source materials.

Applicants should take note that the same members of the Scientific Advice team (CADTH staff and external experts) may provide Scientific Advice for similar or competing drugs.

CADTH Scientific Advice provided to the applicant is not binding on CADTH and will not be considered relevant or be taken into account in regard to any future CADTH assessments or recommendation(s) related to the drug for which Scientific Advice is sought. CADTH Scientific Advice should not be considered representative of any future CADTH position. The CADTH Scientific Advice Program operates independently from the CADTH Common Drug Review, the CADTH pan-Canadian Oncology Drug Review, and its other HTA programs, as well as from the Health Canada regulatory process. Scientific Advice provided to applicants is without prejudice to any intellectual property rights of third parties.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. You may only use, download, print, or copy this document within your organization, and you may not modify or disseminate this document and must give appropriate credit to CADTH and its licensors.